$3.41 Billion is the total value of Avoro Capital Advisors LLC's 32 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | ASCENDIS PHARMAsponsored adr | $259,459,000 | +36.7% | 1,865,000 | -5.3% | 7.62% | -3.8% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $244,305,000 | +26.6% | 8,826,039 | -16.7% | 7.17% | -10.9% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $169,100,000 | +2.9% | 2,000,000 | -17.9% | 4.96% | -27.5% |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $113,103,000 | +94.3% | 5,900,000 | -2.5% | 3.32% | +36.8% |
| MYOK | Sell | MYOKARDIA INC | $112,243,000 | +38.6% | 1,540,000 | -0.8% | 3.30% | -2.4% |
| ATNX | Sell | ATHENEX INC | $80,342,000 | +12.1% | 5,261,437 | -10.7% | 2.36% | -21.1% |
| TCDA | Sell | TRICIDA INC | $58,874,000 | -13.3% | 1,560,000 | -29.1% | 1.73% | -39.0% |
| AMRN | Sell | AMARIN CORP PLCsponsored adr | $40,736,000 | -68.5% | 1,900,000 | -77.7% | 1.20% | -77.8% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $31,797,000 | +2.4% | 349,000 | -3.1% | 0.93% | -27.9% |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $18,960,000 | -39.3% | 3,000,000 | -59.6% | 0.56% | -57.3% |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -285,714 | -100.0% | -0.14% | – |
| ALIM | Exit | ALIMERA SCIENCES INC | $0 | – | -6,240,000 | -100.0% | -0.15% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.16% | – |
| TLGT | Exit | TELIGENT INC | $0 | – | -5,231,206 | -100.0% | -0.21% | – |
| KOD | Exit | KODIAK SCIENCES INC | $0 | – | -500,000 | -100.0% | -0.30% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -371,623 | -100.0% | -0.78% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -684,000 | -100.0% | -0.96% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -887,500 | -100.0% | -1.33% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -2.02% | – |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -1,600,000 | -100.0% | -2.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.